Literature DB >> 30854124

PD-L1 expression patterns in tumour cells and their association with CD8+ tumour infiltrating lymphocytes in clear cell renal cell carcinoma.

Qian Zhu1,2, Mu-Yan Cai1,3, De-Sheng Weng1,2, Jing-Jing Zhao1,2, Qiu-Zhong Pan1,2, Qi-Jing Wang1,2, Yan Tang1,2, Jia He1,2, Min Li1,3, Jian-Chuan Xia1,2.   

Abstract

Purpose: To evaluate the tumour cell PD-L1 (TC-PD-L1) expression patterns in the local microenvironment of clear cell renal cell carcinoma (ccRCC). Materials and
Methods: 30 fresh primary ccRCC tissues were used to detect the association between TC-PD-L1 and CD8+TILs at mRNA level. The in vitro incubation experiment was used to confirm the association between extrinsic TC-PD-L1 expression and IFNγ. A cohort of 135 ccRCC patients treated between January 2009 and August 2013 was included for survival analysis.
Results: Our results confirmed that ccRCC cell lines were capable of expressing PD-L1. The incubation experiment in vitro demonstrated the positive correlation of TC-PD-L1 expression with interferon-gamma (IFNγ). Additionally, survival analysis was investigated in 135 ccRCC patients and found no independent correlation of TC-PD-L1 expression in multivariate analysis, whereas more distinct prognostic differences were detected when TC-PD-L1-positive ccRCC were sub-classified as with or without CD8+ T cell infiltration.
Conclusion: The intrinsic and extrinsic expression patterns are both detected in ccRCC. High positive rate of TC-PD-L1 correlated closely to the strong infiltration of CD8+ TILs. TC-PD-L1-positive ccRCC patients with abundant CD8+ TILs infiltration confer the high risk of death and disease relapse.

Entities:  

Keywords:  PD-L1; clear cell renal cell carcinoma; extrinsic expression; intrinsic expression; local microenvironment

Year:  2019        PMID: 30854124      PMCID: PMC6400669          DOI: 10.7150/jca.29052

Source DB:  PubMed          Journal:  J Cancer        ISSN: 1837-9664            Impact factor:   4.207


  30 in total

Review 1.  Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy.

Authors:  R Houston Thompson; Haidong Dong; Eugene D Kwon
Journal:  Clin Cancer Res       Date:  2007-01-15       Impact factor: 12.531

2.  Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity.

Authors:  O Nakano; M Sato; Y Naito; K Suzuki; S Orikasa; M Aizawa; Y Suzuki; I Shintaku; H Nagura; H Ohtani
Journal:  Cancer Res       Date:  2001-07-01       Impact factor: 12.701

3.  Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma.

Authors:  R Houston Thompson; Michael D Gillett; John C Cheville; Christine M Lohse; Haidong Dong; W Scott Webster; Lieping Chen; Horst Zincke; Michael L Blute; Bradley C Leibovich; Eugene D Kwon
Journal:  Cancer       Date:  2005-11-15       Impact factor: 6.860

4.  Rising incidence of small renal masses: a need to reassess treatment effect.

Authors:  John M Hollingsworth; David C Miller; Stephanie Daignault; Brent K Hollenbeck
Journal:  J Natl Cancer Inst       Date:  2006-09-20       Impact factor: 13.506

5.  Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target.

Authors:  R Houston Thompson; Michael D Gillett; John C Cheville; Christine M Lohse; Haidong Dong; W Scott Webster; Kent G Krejci; John R Lobo; Shomik Sengupta; Lieping Chen; Horst Zincke; Michael L Blute; Scott E Strome; Bradley C Leibovich; Eugene D Kwon
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-29       Impact factor: 11.205

6.  Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.

Authors:  R Houston Thompson; Susan M Kuntz; Bradley C Leibovich; Haidong Dong; Christine M Lohse; W Scott Webster; Shomik Sengupta; Igor Frank; Alexander S Parker; Horst Zincke; Michael L Blute; Thomas J Sebo; John C Cheville; Eugene D Kwon
Journal:  Cancer Res       Date:  2006-04-01       Impact factor: 12.701

7.  Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.

Authors:  Haidong Dong; Scott E Strome; Diva R Salomao; Hideto Tamura; Fumiya Hirano; Dallas B Flies; Patrick C Roche; Jun Lu; Gefeng Zhu; Koji Tamada; Vanda A Lennon; Esteban Celis; Lieping Chen
Journal:  Nat Med       Date:  2002-06-24       Impact factor: 53.440

8.  Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis.

Authors:  Robert C Flanigan; G Mickisch; Richard Sylvester; Cathy Tangen; H Van Poppel; E David Crawford
Journal:  J Urol       Date:  2004-03       Impact factor: 7.450

9.  PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma.

Authors:  R Houston Thompson; Haidong Dong; Christine M Lohse; Bradley C Leibovich; Michael L Blute; John C Cheville; Eugene D Kwon
Journal:  Clin Cancer Res       Date:  2007-03-15       Impact factor: 12.531

10.  Survivin and b7-h1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma.

Authors:  Amy E Krambeck; Haidong Dong; R Houston Thompson; Susan M Kuntz; Christine M Lohse; Bradley C Leibovich; Michael L Blute; Thomas J Sebo; John C Cheville; Alexander S Parker; Eugene D Kwon
Journal:  Clin Cancer Res       Date:  2007-03-15       Impact factor: 12.531

View more
  7 in total

1.  Imaging of Clear Cell Renal Carcinoma with Immune Checkpoint Targeting Aptamer-Based Probe.

Authors:  Stanisław Malicki; Barbara Pucelik; Edyta Żyła; Małgorzata Benedyk-Machaczka; Wojciech Gałan; Anna Golda; Alicja Sochaj-Gregorczyk; Marta Kamińska; João Crispim Encarnação; Barbara Chruścicka; Hans-Peter Marti; Tony Jialiang Chen; Katarzyna Magiera-Mularz; Bartosz Zięba; Tad A Holak; Janusz M Dąbrowski; Anna Czarna; Joanna Kozieł; Piotr Mydel; Grzegorz Dubin
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-01

Review 2.  Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer.

Authors:  Alessandra Raimondi; Pierangela Sepe; Emma Zattarin; Alessia Mennitto; Marco Stellato; Melanie Claps; Valentina Guadalupi; Elena Verzoni; Filippo de Braud; Giuseppe Procopio
Journal:  Front Oncol       Date:  2020-08-12       Impact factor: 6.244

3.  An Avidity-Based PD-L1 Antagonist Using Nanoparticle-Antibody Conjugates for Enhanced Immunotherapy.

Authors:  Jiyoon Bu; Ashita Nair; Mari Iida; Woo-Jin Jeong; Michael J Poellmann; Kara Mudd; Luke J Kubiatowicz; Elizabeth W Liu; Deric L Wheeler; Seungpyo Hong
Journal:  Nano Lett       Date:  2020-06-11       Impact factor: 11.189

4.  Prognostic Value of Long Noncoding RNA DLEU2 and Its Relationship with Immune Infiltration in Kidney Renal Clear Cell Carcinoma and Liver Hepatocellular Carcinoma.

Authors:  Shengqiang Fu; Binbin Gong; Siyuan Wang; Qiang Chen; Yifu Liu; Changshui Zhuang; Zhilong Li; Zhicheng Zhang; Ming Ma; Ting Sun
Journal:  Int J Gen Med       Date:  2021-11-11

5.  Comprehensive analysis of LAMC1 expression and prognostic value in kidney renal papillary cell carcinoma and clear cell carcinoma.

Authors:  Jianrong Bai; Axiu Zheng; Yanping Ha; Xiaoqing Xu; Yaping Yu; Yanda Lu; Shaojiang Zheng; Zhihua Shen; Botao Luo; Wei Jie
Journal:  Front Mol Biosci       Date:  2022-09-16

6.  CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma.

Authors:  Quan Zhou; Yangyang Qi; Zewei Wang; Han Zeng; Hongyu Zhang; Zhaopei Liu; Qiuren Huang; Ying Xiong; Jiajun Wang; Yuan Chang; Qi Bai; Yu Xia; Yiwei Wang; Li Liu; Le Xu; Bo Dai; Jianming Guo; Yu Zhu; Weijuan Zhang; Jiejie Xu
Journal:  J Immunother Cancer       Date:  2020-04       Impact factor: 13.751

Review 7.  Immunotherapy: A new standard in the treatment of metastatic clear cell renal cell carcinoma.

Authors:  Maja Popovic; Gorana Matovina-Brko; Masa Jovic; Lazar S Popovic
Journal:  World J Clin Oncol       Date:  2022-01-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.